Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

News All Time

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

CHEST 2026 Preview: Late-Breakers to Watch Out For

CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Recommended News For You

A small rise in cancer was observed following the 1986 Chernobyl accident.

Laser Therapy Shows Promise for Brain Tumors

Abnormal Shadow on Chest Radiograph

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

Recommended Articles For You

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights 

Screening for Early Changes in Hematopoietic Reserve Among High-Risk Populations 

Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked 

Immunotherapy Tolerance in Older Adults With Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

2.

Medical Journal March 29, 2023

3.

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

4.

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

5.

Study Homes In on Simpler Lung Cancer Screening Criteria

1.

Iron Regulation During Pregnancy and the Postpartum Period

2.

Early Recognition of Immune-Related Adverse Events During Cancer Therapy

3.

Tumor-Specific Fluorescent Peptide Navigation in Surgical Oncology

4.

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options 

5.

Therapeutic RNA Vaccines for Melanoma

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Understanding the Role of Screening in Cancer Prevention

2.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

3.

Sickle Cell Disease Explained

4.

Best Practices in Hematology

5.

Importance of Cancer Screening and Early Detection

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot